Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

146.47 -0.16 (-0.11%)
Streaming Delayed Price Updated: 3:07 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024
Via The Motley Fool
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases. 
Via Benzinga
17 Analysts Assess Biogen: What You Need To Know
 
Via Benzinga
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
Large-Cap Stocks In Trouble - Saturday, Dec. 21
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns. 
Via Talk Markets
Topics Stocks / Equities
Assessing Biogen: Insights From 19 Financial Analysts
 
Via Benzinga
Peeling Back The Layers: Exploring Biogen Through Analyst Insights
 
Via Benzinga
Evaluating Biogen: Insights From 17 Financial Analysts
 
Via Benzinga
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
 
Via Benzinga
Super Micro Computer Teeters On Edge Of Nasdaq 100: Can xAI, Nvidia Help Stabilize Trajectory?
Super Micro faces potential delisting from Nasdaq 100 Index due to underperformance and auditing scandal. Uncertainty surrounds its future. 
Via Benzinga
Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown
Jefferies downgrades Biogen with a reduced price target, citing pipeline setbacks, slow Leqembi sales, and challenges from declining Ocrevus royalties. 
Via Benzinga
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Biogen Analysts Slash Their Forecasts After Q3 Results
 
Via Benzinga
Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum
The biotech giant also raised full-year EPS guidance. 
Via Investor's Business Daily
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over
Via The Motley Fool
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024. 
Via Benzinga
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
From Biogen Inc.
Via GlobeNewswire
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show gradual growth amid market challenges. 
Via Benzinga
This Biogen Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
 
Via Benzinga
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
This Kraft Heinz Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
 
Via Benzinga
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
From Biogen Inc.
Via GlobeNewswire
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
Biogen (BIIB) Q3 2024 Earnings Call Transcript
BIIB earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook
Biogen's Q2 revenue fell 3% to $2.47 billion exceeding estimates, with adjusted EPS of $4.08. Multiple sclerosis sales dipped, while new products buoyed performance. 
Via Benzinga
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
From Biogen Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.